Psychiatry and Neurology, Neurology · Albuquerque, NM
NPI
1386958825
Since 2010
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
500 Walter St NE, Ste 401
Albuquerque, NM, 87102
Phone (505) 727-5910
Groups this clinician bills Medicare through
Medicare paid, 2024
$168K
17,707 services
Medicare patients, 2024
373
Average age 72
Drug cost, 2024
$1.6M
4,110 prescriptions
Company payments, 2025
$3,285
From 32 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vanessa D Licona Sanjuan was code J0585 (injection, onabotulinumtoxina, 1 unit), 16,501 times for 31 patients. In total Vanessa D Licona Sanjuan billed 17,707 services in 34 codes, and Medicare paid $168K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-04-19.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 16,501 | 31 | $4.96 | $82K |
| 99214 Office E&M - Established | Office | 198 | 149 | $88.71 | $18K |
| 99213 Office E&M - Established | Office | 169 | 144 | $57.48 | $9,714 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 158 | 30 | $45.97 | $7,264 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 131 | 110 | $12.55 | $1,644 |
| 64615 Musculoskeletal | Office | 90 | 30 | $107.27 | $9,654 |
| 99204 Office E&M - New | Office | 69 | 69 | $99.03 | $6,833 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 64 | 24 | $34.44 | $2,204 |
| 99205 Office E&M - New | Office | 62 | 62 | $156.03 | $9,674 |
| 99215 Office E&M - Established | Office | 45 | 43 | $119.60 | $5,382 |
| 95886 Electrical Nerve Conductivity | Office | 31 | 31 | $70.41 | $2,183 |
| 95909 Electrical Nerve Conductivity | Office | 23 | 23 | $92.37 | $2,124 |
| 95885 Electrical Nerve Conductivity | Office | 19 | 16 | $43.20 | $821 |
| 95819 Neurologic | Office | 16 | 16 | $75.44 | $1,207 |
| 95908 Electrical Nerve Conductivity | Office | 15 | 15 | $77.92 | $1,169 |
By year: 2022 $151K for 18,681 services; 2023 $155K for 18,979 services; 2024 $168K for 17,707 services.
Medicare prescription drug claims, 2024
In 2024, the drug Vanessa D Licona Sanjuan prescribed most often to Medicare patients was Memantine Hcl, with 439 prescriptions and refills. In total Vanessa D Licona Sanjuan wrote 4,110 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Memantine Hcl Generic | 439 | 639 | 90 | $8,144 |
| Donepezil Hcl Generic | 194 | 364 | 56 | $1,759 |
| Aimovig Autoinjector Erenumab-Aooe | 171 | 201 | 29 | $142K |
| Levetiracetam Generic | 163 | 355 | 49 | $4,863 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 162 | 308 | 46 | $3,431 |
| Gabapentin Generic | 160 | 249 | 49 | $2,311 |
| Pregabalin Generic | 117 | 167 | 31 | $2,398 |
| Zonisamide Generic | 117 | 184 | 23 | $4,340 |
| Emgality Pen Galcanezumab-Gnlm | 115 | 152 | 25 | $115K |
| Mirtazapine Generic | 102 | 143 | 36 | $2,123 |
| Primidone Generic | 99 | 214 | 33 | $2,214 |
| Nurtec Odt Rimegepant Sulfate | 97 | 100 | 25 | $159K |
| Duloxetine Hcl Generic | 96 | 149 | 29 | $1,358 |
| Sertraline Hcl Generic | 92 | 153 | 28 | $893 |
| Lamotrigine Generic | 86 | 160 | 21 | $1,959 |
Brand drugs: 761 claims; generic drugs: 3,290 claims; opioid claims: 62.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vanessa D Licona Sanjuan $3,285 ($3,285 in general payments such as food, travel and fees) from 32 companies. The largest payer was Abbvie Inc. with $789.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.